{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:32:12Z","timestamp":1786422732031,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess changes in renal profile over time and short-term estimated glomerular filtration rate (eGFR) after antiretroviral treatment (ART) initiation or switch in an Italian HIV cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed data from SCOLTA, a multicenter prospective pharmacovigilance cohort of people with HIV (PWH) initiating or switching ART in routine care. Participants enrolled between 2007 and 2024 with baseline eGFR \u226530 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and at least one renal assessment at 24 \u00b1 4 weeks and\/or 48 \u00b1 4 weeks were included. Renal profile was assessed across calendar periods, and eGFR changes from baseline to week 24 and from week 24 to week 48 were evaluated using unadjusted analyses and multivariable general linear models including either drug cohort or calendar period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 5170 participants, 25.7% were women and 18.2% were ART-na\u00efve. Renal profile changed over time as the cohort became older and more treatment-experienced. The main decline in eGFR occurred during the first 24 weeks after ART initiation or switch, whereas changes from week 24 to week 48 were minimal. In adjusted analyses, ART-na\u00efve participants showed a greater early decline in eGFR than ART-experienced individuals (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001). TDF-associated changes were not consistent across the two adjusted models. Kidney-related treatment discontinuations were uncommon (26\/5170, 0.5%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In PWH with baseline eGFR \u226530 mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , kidney-related treatment discontinuations were uncommon. Renal profile changed over time, and the main decline in creatinine-based eGFR occurred during the first 24 weeks after ART initiation or switch, followed by relative stability between weeks 24 and 48.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1898349","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:49Z","timestamp":1786422109000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Changing renal profile and early eGFR dynamics after ART initiation or switch in a large Italian HIV cohort"],"prefix":"10.3389","volume":"13","author":[{"given":"Paolo","family":"Maggi","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, \u201cKore\u201d University of Enna","place":["Enna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Ceccarelli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, \u201cKore\u201d University of Enna","place":["Enna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Delfina","family":"Ricci","sequence":"additional","affiliation":[{"name":"Fondazione ASIA","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[{"name":"Division I of Infectious and Tropical Diseases, ASL Citt\u00e0 di Torino","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Menzaghi","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio","place":["VA, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Squillace","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliera Metropolitana","place":["Genoa, Italy"]},{"name":"Department of Health's Sciences, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Clinic, Department of Medicine and Surgery, University of Perugia","place":["Perugia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Piconi","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, A. Manzoni Hospital","place":["Lecco, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari","place":["Sassari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Francesco","family":"Pellican\u00f2","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"AOU Infectious and Tropical Diseases, Careggi Hospital","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, IRCCS Azienda Ospedaliera Metropolitana","place":["Genoa, Italy"]},{"name":"Department of Health's Sciences, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori","place":["Monza, Italy"]},{"name":"University of Milano-Bicocca","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1093\/cid\/ciu617","article-title":"Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America","volume":"59","author":"Lucas","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.kint.2017.11.007","article-title":"Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"93","author":"Swanepoel","year":"2018","journal-title":"Kidney Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.kint.2022.06.021","article-title":"HIV at 40: kidney disease in HIV treatment, prevention, and cure","volume":"102","author":"Lucas","year":"2022","journal-title":"Kidney Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.5414\/CNP83S032","article-title":"HIV and chronic kidney disease","volume":"83","author":"Naicker","year":"2015","journal-title":"Clin Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12981-020-00266-3","article-title":"Contemporary issues and new challenges in chronic kidney disease amongst people living with HIV","volume":"17","author":"Heron","year":"2020","journal-title":"AIDS Res Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12882-019-1335-9","article-title":"Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting","volume":"20","author":"Kabor\u00e9","year":"2019","journal-title":"BMC Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/cpt.70164","article-title":"Cardiovascular-Kidney-Metabolic syndrome in people with HIV: an emerging frontier for clinical pharmacology","volume":"119","author":"Devanathan","year":"2025","journal-title":"Clin Pharmacol Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","article-title":"Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study","volume":"3","author":"Mocroft","year":"2016","journal-title":"Lancet HIV."},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40121-014-0056-4","article-title":"Protease inhibitors and renal function in patients with HIV Infection: a systematic review","volume":"4","author":"Bagnis","year":"2015","journal-title":"Infect Dis Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"ofw053","DOI":"10.1093\/ofid\/ofw053","article-title":"Evaluation of serum creatinine changes with integrase inhibitor use in human immunodeficiency virus-1 infected adults","volume":"3","author":"Lindeman","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/hiv.70220","article-title":"Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort","volume":"27","author":"Leleux","year":"2026","journal-title":"HIV Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.qai.0000164248.56722.3c","article-title":"An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir\/ritonavir","volume":"39","author":"Bonfanti","year":"2005","journal-title":"J Acquir Immune Defic Syndr."},{"key":"B13","unstructured":"MMWR Recomm Rep [Internet]\n          \n          1\n          19\n          1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for Aids Among Adolescents and Adults\n          41\n          1992"},{"key":"B14","first-page":"144","article-title":"Novel antiretroviral drugs and renal function monitoring of HIV patients","volume":"16","author":"Maggi","year":"2014","journal-title":"AIDS Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40620-020-00701-8","article-title":"Therapeutic management of HIV-infected patients with chronic kidney disease","volume":"33","author":"Alfano","year":"2020","journal-title":"J Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1186\/s12879-019-4184-z","article-title":"Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study","volume":"19","author":"Maggi","year":"2019","journal-title":"BMC Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"k5301","DOI":"10.1136\/bmj.k5301","article-title":"Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium","volume":"364","author":"Chang","year":"2018","journal-title":"BMJ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e089783","DOI":"10.1136\/bmjopen-2024-089783","article-title":"Rate of decline in kidney function with age: a systematic review","volume":"14","author":"Guppy","year":"2024","journal-title":"BMJ Open."},{"key":"B19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ijantimicag.2017.04.021","article-title":"Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial","volume":"50","author":"Achhra","year":"2017","journal-title":"Int J Antimicrob Agents."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.biopha.2007.04.008","article-title":"Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project","volume":"62","author":"Madeddu","year":"2008","journal-title":"Biomed Pharmacother."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1898349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:52Z","timestamp":1786422112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1898349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1898349"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1898349","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1898349"}}